{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05765734",
            "orgStudyIdInfo": {
                "id": "10073010"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-502595-23",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Taiho Oncology, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of TAS3351 in NSCLC Patients With EGFRmt",
            "officialTitle": "A Phase 1/2 Study of TAS3351 in Patients With Advanced Non-Small Cell Lung Cancer and EGFR Mutations",
            "acronym": "TAS3351",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-in-nsclc-patients-with-egfrmt"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-08",
            "studyFirstSubmitQcDate": "2023-03-08",
            "studyFirstPostDateStruct": {
                "date": "2023-03-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Taiho Oncology, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human, open label, Phase 1/2 study to investigate the safety and efficacy of TAS3351 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.",
            "detailedDescription": "This study will be conducted in 3 parts (i.e. dose escalation, dose expansion, and a phase 2 portion). The dose escalation part will investigate the safety and determine the recommended phase 2 dose and the recommended dosing regimen of TAS3351 administered orally. The dose expansion part will explore the efficacy of TAS3351 in NSCLC patients with C797S EGFR mutations. The phase 2 part will assess the efficacy of TAS3351 in NSCLC patients with C797S EGFR mutations."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Small Cell Lung Cancer"
            ],
            "keywords": [
                "Non-Small Cell Lung Cancer",
                "NSCLC",
                "EGFR mutation",
                "C797S mutation",
                "TAS3351"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "TAS3351 Part A (Dose Escalation)",
                    "type": "EXPERIMENTAL",
                    "description": "Dose escalation will assess the safety and determine the recommended phase 2 dose and regimen of TAS3351 administered orally.",
                    "interventionNames": [
                        "Drug: TAS3351 oral administration"
                    ]
                },
                {
                    "label": "TAS3351 Part B (Dose Expansion)",
                    "type": "EXPERIMENTAL",
                    "description": "TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose determined in Part A.",
                    "interventionNames": [
                        "Drug: TAS3351 oral administration"
                    ]
                },
                {
                    "label": "TAS3351 Part C (Phase 2)",
                    "type": "EXPERIMENTAL",
                    "description": "To assess efficacy of TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose.",
                    "interventionNames": [
                        "Drug: TAS3351 oral administration"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TAS3351 oral administration",
                    "description": "TAS3351 will be administered orally",
                    "armGroupLabels": [
                        "TAS3351 Part A (Dose Escalation)",
                        "TAS3351 Part B (Dose Expansion)",
                        "TAS3351 Part C (Phase 2)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose Escalation: To investigate the safety and determine the recommended Phase 2 dose and dosing schedule of TAS3351",
                    "description": "Adverse Events",
                    "timeFrame": "baseline through cycle 1(each cycle is 21 days)"
                },
                {
                    "measure": "Dose Escalation: To investigate the safety and determine the recommended Phase 2 dose and dosing schedule of TAS3351",
                    "description": "Incidence of dose limiting toxicities (DLTs)",
                    "timeFrame": "baseline through cycle 1(each cycle is 21 days)"
                },
                {
                    "measure": "Dose Expansion: To explore the efficacy of TAS3351",
                    "description": "Objective Response Rate (ORR)",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Phase 2: To assess the efficacy of TAS3351",
                    "description": "Objective Response Rate (ORR)",
                    "timeFrame": "estimated 3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Dose Escalation:To evaluate the antitumor activity of TAS3351",
                    "description": "Objective response rate (ORR)",
                    "timeFrame": "estimated 20 months"
                },
                {
                    "measure": "Dose Escalation:To evaluate the antitumor activity of TAS3351",
                    "description": "Duration of response (DoR)",
                    "timeFrame": "estimated 20 months"
                },
                {
                    "measure": "Dose Escalation:To evaluate the antitumor activity of TAS3351",
                    "description": "Disease control rate (DCR)",
                    "timeFrame": "estimated 20 months"
                },
                {
                    "measure": "Dose Escalation: To evaluate the antitumor activity of TAS3351",
                    "description": "Progression free survival (PFS)",
                    "timeFrame": "estimated 20 months"
                },
                {
                    "measure": "Dose Escalation: To evaluate the antitumor activity of TAS3351",
                    "description": "Overall Survival (OS)",
                    "timeFrame": "estimated 20 months"
                },
                {
                    "measure": "Dose Escalation: To characterize the pharmacokinetics (PK) of TAS3351",
                    "description": "Evaluate the maximum plasma concentration (Cmax)",
                    "timeFrame": "Cycle 1 Day 1 through cycle 1 Day 15 (21-Day cycle)"
                },
                {
                    "measure": "Dose Escalation: To characterize the pharmacokinetics (PK) of TAS3351",
                    "description": "Area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "ECycle 1 Day 1 through cycle 1 Day 15 (21-Day cycle)"
                },
                {
                    "measure": "Dose Expansion: To confirm the safety and tolerability of TAS3351 at the recommended phase 2 dose and dosing schedule",
                    "description": "Adverse Events (AEs)",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Duration of response (DoR) by ICR",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Progression Free Survival (PFS) by ICR",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Disease Control Rate (DCR) by ICR",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Objective Response Rate (ORR) by Investigator Assessment",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Duration of Response (DoR) by Investigator Assessment",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Progression Free Survival (PFS) by Investigator Assessment",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Disease Control Rate (DCR) by Investigator Assessment",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Intracranial Objective Response Rate (icORR)",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Intracranial Duration of Response (icDOR)",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Dose Expansion: To further explore the anti-tumor efficacy of TAS3351",
                    "description": "Overall survival (OS)",
                    "timeFrame": "estimated 9 months"
                },
                {
                    "measure": "Phase 2: To evaluate the safety and tolerability of TAS3351",
                    "description": "Adverse Events (AEs)",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Duration of response (DoR) by ICR",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Progression Free Survival (PFS) by ICR",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Disease Control Rate (DCR) by ICR",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Objective Response Rate (ORR) by Investigator Assessment",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Duration of Response (DoR) by Investigator Assessment",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Progression Free Survival (PFS) by Investigator Assessment",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Disease Control Rate (DCR) by Investigator Assessment",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Intracranial Objective Response Rate (icORR)",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Intracranial Duration of Response (icDOR)",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2: To further assess the efficacy of TAS3351",
                    "description": "Overall survival (OS)",
                    "timeFrame": "estimated 3 years"
                },
                {
                    "measure": "Phase 2:To evaluate patient reported outcomes (PROs)",
                    "description": "responses to patient questionnaires",
                    "timeFrame": "estimated 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced, non-resectable or metastatic NSCLC\n* Have adequate organ function\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Has tumor tissue available to allow for analysis of EGFRmt status\n\nDose Escalation:\n\n\u2022 Has any EGFRmt status\n\nDose Escalation back-fill part, Dose Expansion and Phase II:\n\n* Has any sensitizing EGFRmt and a confirmed C797S EGFRmt\n* Has measurable disease per RECIST v1.1\n\nExclusion Criteria:\n\n* Participating in medical research not compatible with this study\n* Symptomatic and unstable CNS metastases\n* Have not recovered from prior cancer treatment\n* Have a significant cardiac condition\n* Are a pregnant or breastfeeding female\n* A serious illness or medical condition\n* Unable to swallow or digest pills",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Taiho Oncology, Inc",
                    "role": "CONTACT",
                    "phone": "844-878-2446",
                    "email": "medicalinformation@taihooncology.com"
                }
            ],
            "locations": [
                {
                    "facility": "Georgetown University - Lombardi Comprehensive Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20007",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "202-444-4000",
                            "email": "chul.kim@gunet.georgetown.edu"
                        },
                        {
                            "name": "Kim Chul",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "Tennessee Oncology",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "615-329-7274",
                            "email": "mjohnson@tnonc.com"
                        },
                        {
                            "name": "Melissa Johnson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University of Texas M. D. Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "713-792-6363",
                            "email": "xle1@mdanderson.org"
                        },
                        {
                            "name": "Xiuning Le",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Next Oncology - Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "703-280-5390",
                            "email": "aspira@nextoncology.com"
                        },
                        {
                            "name": "Alexander Spira",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Institut Gustave Roussy",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Villejuif cedex",
                    "state": "Val De Marne",
                    "zip": "94805",
                    "country": "France",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+33549444444",
                            "email": "david.planchard@gustaveroussy.fr"
                        },
                        {
                            "name": "David Planchard",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Universitaetsklinikum Koeln",
                    "status": "RECRUITING",
                    "city": "Koeln",
                    "state": "Nordrhein Westfalen",
                    "zip": "50937",
                    "country": "Germany",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+4922147889050",
                            "email": "juergen.wolf@uk-koeln.de"
                        },
                        {
                            "name": "Juergen Wolf",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.93333,
                        "lon": 6.95
                    }
                },
                {
                    "facility": "IEO Istituto Europeo di Oncologia",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Milano",
                    "zip": "20141",
                    "country": "Italy",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "390257489599",
                            "email": "giuseppe.curigliano@ieo.it"
                        },
                        {
                            "name": "Giuseppe Curigliano",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "National Cancer Center Hospital East",
                    "status": "RECRUITING",
                    "city": "Kashiwa-shi",
                    "state": "Chiba-Ken",
                    "zip": "277-8577",
                    "country": "Japan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+81471331111",
                            "email": "kgoto@east.ncc.go.jp"
                        },
                        {
                            "name": "Koichi Goto",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.86224,
                        "lon": 139.97732
                    }
                },
                {
                    "facility": "Shizuoka Cancer Center",
                    "status": "RECRUITING",
                    "city": "Sunto-gun",
                    "state": "Shizuoka-Ken",
                    "zip": "411-8777",
                    "country": "Japan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+81559895222",
                            "email": "ha.murakami@scchr.jp"
                        },
                        {
                            "name": "Haruyasu Murakami",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ]
                },
                {
                    "facility": "Cancer Institute Hospital of JFCR",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Koto-Ku",
                    "zip": "135-8550",
                    "country": "Japan",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "81335200111",
                            "email": "ken.uchibori@jfcr.or.jp"
                        },
                        {
                            "name": "Uchibori Ken",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.66667,
                        "lon": 139.81718
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+82220723559",
                            "email": "gabriel9@snu.ac.kr"
                        },
                        {
                            "name": "Kim Tae Min",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Seul",
                    "zip": "5505",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "82230103214",
                            "email": "leedaeho@amc.seoul.kr"
                        },
                        {
                            "name": "Lee Dae Ho",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Antoni van Leeuwenhoek",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Amsterdam",
                    "zip": "1066 CX",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+31205122958",
                            "email": "g.ruiter@nki.nl"
                        },
                        {
                            "name": "Gerrina Ruiter",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "Leiden University Medical Center (LUMC)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Leiden",
                    "zip": "2333ZA",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+31205129098",
                            "email": "e.f.smit@lumc.nl"
                        },
                        {
                            "name": "Egbert Smit",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.15833,
                        "lon": 4.49306
                    }
                },
                {
                    "facility": "Hospital Universitari Vall d'Hebron",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Barcelona",
                    "zip": "8035",
                    "country": "Spain",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "34934894350",
                            "email": "efelip@vhio.net"
                        },
                        {
                            "name": "Enriqueta Felip Font",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario 12 de Octubre",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Madrid",
                    "zip": "28401",
                    "country": "Spain",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+34955013068",
                            "email": "lpazaresr@seom.org"
                        },
                        {
                            "name": "Luis Paz-Ares Rodriguez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "The Christie Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Manchester",
                    "state": "Greater Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "+441612912829",
                            "email": "yvonne.summers@nhs.net"
                        },
                        {
                            "name": "Yvonne Summers",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}